Abstract
Xanthohumol (XN) and its related compounds were evaluated for their cytotoxicity against four different human cancer cell lines, A549 (lung), SK-OV-3 (ovarian), SK-MEL-2 (melanoma), and HCT-15 (colon) using a sulforhodamine B assay. XN showed the most active cytotoxicity against the human cancer cell lines. Isoxanthohumol, 8-prenylnaringenin, and xanthohumol 4’-O-β-D-glucopyranoside showed comparable cytotoxicity and (2S)-5-methoxy-8-prenylnaringe-nin 7-O-β-D-glucopyranoside was the least cytotoxic compound. The anticancer properties of XN, the most active cytotoxic compound, were further investigated. XN showed an inhibitory effect on the activity of DNA topoisomerase I (topo I), which was measured from the relaxation of supercoiled DNA. The inhibition of topo I by XN might explain the cytotoxicity against the human cancer cell lines. Moreover, the expression of the drug efflux genes was investigated to predict the drug resistance. XN clearly decreased the mRNA levels of ABCB1 (MDR1), ABCC1 (MRP1), ABCC2 (MRP2), and ABCC3 (MRP3). These results suggest that XN has anticancer properties by inhibiting the topo I activity and it might be used in conjunction with other anticancer chemotherapeutic agents to reduce the drug resistance inhibiting the efflux drug transporters.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albini, A., Dell’Eva, R., Vene, R., Ferrari, N., Buhler, D. R., Noonan, D. M., and Fassina, G., Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NF-kappaB and Akt as targets.FASEB J., 20, 527–529 (2006).
Chen, A. Y. and Liu, L. F., DNA topoisomerase: essential enzymes and lethal targets.Annu. Rev. Pharmacol. Toxicol., 34, 191- 218 (1994).
Clark, A. M., McChesney, J. D., and Hufford, C. D., The use of microorganisms for the study of drug metabolism.Med. Res. Rev., 5, 231–253 (1985).
D’Arpa, P. and Liu, L. F., Topoisomerase-targeting antitumor drugs.Biochim. Biophys. Acta, 989, 163–177 (1989).
Dietz, B. M., Kang, Y. H., Liu, G., Eggler, A. L., Yao, P., Chadwick, L. R., Pauli, G. F., Farnsworth, N. R., Mesecar, A. D., van Breemen, R. B., and Bolton, J. L., Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase.Chem. Res. Toxicol., 18, 1296–1305 (2005).
Fukuda, M., Nishio, K., Kanzawa, F., Ogasawara, H., Ishida, T., Arioka, H., Bojanowski, K., Oka, M., and Saijo, N., Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.Cancer Res., 56, 789–793 (1996).
Gerhauser, C., Alt, A., Heiss, E., Gamal-Eldeen, A., Klimo, K., Knauft, J., Neumann, I., Scherf, H. R., Frank, N., Bartsch, H., and Becker, H., Cancer chemopreventive activity of Xanthohumol a natural product derived from hop.Mol. Cancer Ther., 1, 959–969 (2002).
Gottesman, M. M., Fojo, T., and. Bates, S. E., Multidrug resistance in cancer: role of ATP-dependent transporter.Nat. Rev. Cancer, 2, 48–58 (2002).
Henderson, M. C., Miranda, C. L., Stevens, J. F., Deinzer, M. L., and Buhler, D. R., In vitro inhibition of human P450 enzymes by prenylated flavonoids from hops,Humulus lupulus. Xenobiotica, 30, 235–251 (2000).
Hsiang, Y. H., Hertzberg, R., Hecht, S., and Liu, L. F., Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.J. Biol. Chem., 260, 14873–14878 (1985).
Huang, R., Murry D. J., Kolwankar, D., Hall, S. D., and Foster, D. R., Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines.Biochem Pharmacol., 71, 1695–1704 (2006).
Jain, A. C., Gupta, R. C., and Sarpal, P. D., Synthesis of (±) lupinifolin, di-O-methyl xanthohumol and isoxanthohumol and related compounds.Tetrahedron, 34, 3563–3567 (1978).
Kim, H. J. and Lee, I.-S., Microbial metabolism of the prenylated chalcone xanthohumol.J. Nat. Prod., 69, 1522–1524 (2006).
Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F., and Borst, P., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.Cancer Res., 57, 3537–3547 (1997).
Kweon, M. H., Adhami, V. M., Lee, J. S., and Mukhtar, H., Constitutive overexpression of Nrf2-dependent heme oxygenase-1 in A549 cells contributes to resistance to apoptosis induced by epigallocatechin 3-gallate.J. Biol. Chem., 281, 33761–33772 (2006).
Liu, G., Eggler, A. L., Dietz, B. M., Mesecar, A. D., Bolton, J. L., Pezzuto, J. M., and van Breemen, R. B., Screening method for the discovery of potential cancer chemoprevention agents based on mass spectrometric detection of alkylated Keap1.Anal. Chem., 77, 6407–6414 (2005).
Minemura, M., Tanimura, H., and Tabor, E., Overexpression of multidrug resistance genes MDR1 and cMOAT in human hepatocellular carcinoma and hepatoblastoma cell lines.Int. J.Oncol., 15, 559–563 (1999).
Miranda, C. L., Aponso, G. L., Stevens, J. F., Deinzer, M. L., and Buhler, D. R., Prenylated chalcones and flavanones as inducers of quinone reductase in mouse Hepa 1c1c7 cells.Cancer Lett., 149, 21–29 (2000).
Miranda, C. L., Stevens, J. F., Helmlich, A., Henderson, M. C., Rodriguez, R. J., Yang, Y. H., Deinzer, M. L., Barnes, D. W., and Buhler, D. R., Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines.Food Chem. Toxicol., 37, 271–285 (1999).
Miranda, C. L., Yang, Y. H., Henderson, M. C., Stevens, J. F., Santana-Rios, G., Deinzer, M. L., and Buhler, D.R., Prenyl- flavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cDNA-expressed human CYP1A2.Drug Metab. Dispos., 28, 1297–1302 (2000).
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R., New colorimetric cytotoxicity assay for anticancer-drug screening.J. Natl. Cancer Inst., 82, 1107–1112 (1990).
Slichenmyer, W. J., Rowinsky, E. K., Donehower, R. C., and Kaufmann, S. H., The current status of camptothecin analogues as antitumor agents.J. Natl. Cancer Inst., 85, 271- 291 (1993).
Stevens, J. F. and Page, J. E., Xanthohumol and related prenyl-flavonoids from hops and beer: to your good health!Photochemistry, 65, 1317–1330 (2004).
Stevens, J. F., Ivancic, M., Hsu, V. L., and Deinzer, M. L., Prenyl- flavonoids fromHumulus lupulus.Phytochemistry, 44, 1574–1585 (1997).
Venisetty, R. K. and Ciddi, V., Application of microbial biotransformation for the new drug discovery using natural drugs as substrates.Curr. Pharm. Biotechnol., 4, 153–167 (2003).
Wang, J. C., DNA topoisomerases.Annu. Rev. Biochem., 65, 635–692 (1996).
Young, L. C., Campling, B. G., Cole, S. P. C., Deeley R. G., and Gerlach, J. H., Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels.Clin. Cancer Res., 7, 1798–1804 (2001).
Zhao, F., Nozawa, H., Daikonnya, A., Kondo, K., and Kitanaka, S. Inhibitors of nitric oxide production from hops(Humulus lupulus L.Biol. Pharm. Bull., 26, 61–65 (2003).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, S.H., Kim, H.J., Lee, J.S. et al. Inhibition of topoisomerase I activity and efflux drug transporters’ expression by xanthohumol from hops. Arch Pharm Res 30, 1435–1439 (2007). https://doi.org/10.1007/BF02977368
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02977368